Welcome to the LAG-3 Targeted Drug Development Summit

With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.

Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.

Ensure your LAG-3 program reaches full clinical potential through hearing from experts discuss:

HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview
HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview
HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview
HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview

The progress that has been made and challenges faced in bispecific antibody based approaches

Improving combination therapy regimens

Better understanding the underpinning biology of LAG-3 as a cancer target

Utilizing biomarkers to understand the interplay between PD-1 and LAG-3

Join translational and clinical experts in LAG-3 development from Roche, BMS, F-STAR, Regeneron, Immutep, Macrogenics, University of Pittsburgh and more.

Expert Speaker Faculty

Andrew Pierce

Vice President - Translational Biology

Crescendo Biologics

Giuseppe Gullo

Clinical Lead

Regeneron Pharmaceuticals

Xiaobo Mao

Associate Professor

Johns Hopkins School of Medicine

Yvonne Saenger

Director of Melanoma Immunotherapy

Columbia University

Who Attends?

24181 (2)
24181 (4)
24181 (3)
24181 (5)
24181